Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07042919Phase 1Recruiting

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

Role: lead

NCT05251038Phase 1Withdrawn

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Role: lead

NCT02082691Unknown

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Role: lead

All 3 trials loaded